SignalXSignalX

PACB PACIFIC BIOSCIENCES OF CALIFORNIA, INC.

8-K Current Report
Filed: March 5, 2026
Health Care
Laboratory Analytical Instruments
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. Overview

PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) 8-K current report filed with SEC EDGAR on March 5, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.

Reported 8-K Items
2 items

  • Item 5.02: Departure/Election of Directors or Officers
  • Item 7.01: Regulation FD Disclosure

AI Filing Analysis
8-K

Item 5.02 · Departure/Election of Directors or Officers

  • • Board expanded to 10 directors; Christopher Gibson, Ph.D. appointed Class I director effective March 3, 2026
  • • Gibson assigned to Science and Technology Committee — signals focus on scientific/R&D credibility for PACB's genomics platform
+2 more insights

Item 7.01 · Regulation FD Disclosure

  • • Dr. Gibson appointed to a key role at Pacific Biosciences, announced via press release dated March 5, 2026
  • • Leadership change potentially signals strategic or scientific direction shift — full terms in Exhibit 99.1

Other PACIFIC BIOSCIENCES OF CALIFORNIA, INC. 8-K Filings

8-K Mar 6, 2026

Get deeper insights on PACIFIC BIOSCIENCES OF CALIFORNIA, INC.

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.